Please assess the completion status of the following clinical trial:

Trial Title: Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Male or female patients, at least 50 years of age.~2. Documented diagnosis of OA of the knee for at least 6 months~3. The study knee has OA with Grade 2 to 3 severity based on the Kellgren Lawrence grades~4. Patients with patient related visual analogue scale (VAS) score of 5.0 to 9.0 at baseline.~5. Willing and able to comply with study procedures and provide written informed consent.~Main Exclusion Criteria:~1. Patients who received systemic corticosteroids within the last 30 days prior to dosing.~2. Patients who use prohibited medications within 7 days prior to study drug administration or any pain control medication including acetaminophen within 48 hours prior to study drug administration.~3. Patients who use prohibited medications other than acetaminophen and oral NSAIDs from screening visit to 7 days prior to study drug administration.~4. Documented history and confirmed autoimmune disease~5. History of post-traumatic knee arthritis, or evidence of intra articular bleeding of the study knee~6. History of infective arthritis~7. Unstable study knee joint~8. Use of IA corticosteroid, hyaluronic acid, or other IA injection in the study knee within 3 months prior to the screening visit.~9. A history of treated malignancy which is disease free for ≤ 5 years prior to the screening visit~10. Uncontrolled and unstable concurrent medical or psychiatric illness, that will jeopardize the safety of the patient~11. Use of any chemotherapeutic or systemic immunosuppressant agents for inflammatory diseases within 6 months prior to the screening visit.~12. Current use of anticoagulants, including warfarin, heparin, low molecular weight heparin, or dabigatran.~13. Abnormalities of laboratory parameters as described below will qualify for exclusion:~    * hemoglobin \< 8 g/dL;~   * total white blood cell count \< 4000/ µL;~   * serum bilirubin/ alanine aminotransferase/ aspartate aminotransferase \> 2 times upper limit of normal (ULN) for the laboratory reference ranges;~   * serum creatinine \> 2 times ULN for the laboratory reference range;~   * serum uric acid \> ULN for the laboratory reference range;~   * prothrombin time/International Normalized Ratio \> ULN for the laboratory reference range.~14. Contraindication to undergoing magnetic resonance imaging (MRI)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TLC599 LD group (Type: EXPERIMENTAL): 12 mg DSP with 100 µmol PL (1.0 mL)
- TLC599 HD group (Type: EXPERIMENTAL): 18 mg DSP with 150 µmol PL (1.5 mL)
- Placebo group (Type: PLACEBO_COMPARATOR): 1.5 mL normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).